Glucagon-like peptide-1 (7-36 amide) (GLP-1) is known to increase insulin release when given as a bolus in the fasted and fed state. GLP-1 also increases glucose uptake and lipid synthesis in cultured adipocytes. In this study we investigated the effects of GLP-1 on glucose uptake and on the levels of expression of the facilitative glucose transporters, GLUT1 and GLUT4, in fully differentiated 3T3-L1 adipocytes. Cells were incubated with GLP-1 (10 n) with or without insulin (10 and 100 n) for 24 h. Under these conditions, GLP-1 alone caused an increase in basal and acute insulin-stimulated glucose uptake along with an increase in GLUT1 and GLUT4 protein levels.
INTRODUCTION
Glucagon-like peptide-1 (7-36 amide) (GLP-1) is a gastrointestinal peptide that is known to be insulinotropic to the cell of the pancreas (Orskov 1992 , Wang et al. 1995 . It belongs to a class of peptides known as incretins, which enhance the endocrine function of the pancreas (Creutzfeldt & Ebert 1985) . It has also been shown to increase glucose disposal in both healthy (D'Alessio et al. 1994 ) and diabetic subjects (Gutniak et al. 1992) . GLP-1 has been reported to increase cyclic AMP (cAMP) in insulin-producing cells (Drucker et al. 1987) but not in muscle and liver, where it acutely augments glycogen synthesis . Recently we have shown that short-term incubation with GLP-1 increases insulin-mediated glucose uptake in 3T3-L1 adipocytes and that GLP-1 receptors are present on these cells (Egan et al. 1994) . At least five facilitative glucose transporters have so far been identified, sequenced, and characterized among different cell types (Gould & Bell 1990 , Kahn 1992 . One of these transporters, GLUT4, is responsible for the acute insulin-induced stimulation of glucose transport in 3T3-L1 adipocytes (Kaestner et al. 1991 , Czech et al. 1992 . In addition to its acute effects, prolonged exposure to insulin has detrimental effects on glucose transport. Exposure of 3T3-L1 adipocytes to insulin or cAMP for 24 h causes a down-regulation of GLUT4, both at the mRNA and protein levels, and a decrease in insulinmediated glucose transport (Kaestner et al. 1991 , Flores-Riveros et al. 1993 .
In this study, we investigated the effects of a 24-h treatment with GLP-1, in the absence or presence of insulin, on the expression of levels of GLUT4 and GLUT1 mRNA and protein, and on glucose uptake. Changes in cAMP levels, insulin binding, and insulin receptor mRNA levels were also monitored under the same conditions. This allowed us to ascertain if prolonged exposure to GLP-1 had any modulatory effects by itself or on insulin action in cultured fat cells.
MATERIALS AND METHODS

Materials
Murine 3T3-L1 fibroblasts were obtained from the American Type Culture Collection (Rockville, MD, USA). Dulbecco's modified Eagle's medium (DMEM) and sera were purchased from Gibco (Grand Island, NY, USA), 2-deoxy-- [2, H]glucose (30-60 Ci/mmol) and [ 32 P]dCTP from Amersham Corporation (Arlington Heights, IL, USA), 2-deoxy--glucose and insulin from Sigma (St Louis, MO, USA), GLP-1, exendin-4, and exendin-(9-39) from Bachem (Torrence, CA, USA), and tissue culture plates from Costar (Cambridge, MA, USA).
Cell cultures
The 3T3-L1 fibroblasts were grown in DMEM containing 24 m glucose, 10% calf serum, 50 units/ml penicillin and 50 µg/ml streptomycin sulfate. They were maintained in a humidified incubator with 95% air and 5% CO 2 at 37 C, and then induced to differentiate as previously described (Egan et al. 1994) . Cells were routinely used on the eighth to tenth day after the start of differentiation.
Prior to each experiment, the culture medium was changed to DMEM containing 6 m glucose and 10% fetal bovine serum (FBS). Cells were incubated with insulin in the absence or presence of GLP-1 for 24 h with medium change every 8 h with fresh medium containing the same mixture as indicated in the experimental design.
2-Deoxyglucose uptake
A modification of a method by Bernier et al. (1988) was used for the measurements of 2-deoxyglucose uptake. Briefly, 3T3-L1 fibroblasts were grown and differentiated in 12-well culture plates. After 24-h pretreatment with insulin, GLP-1 or both together, cells were washed twice and incubated with 500 µl Krebs-Ringer phosphate (KRP) buffer for 2 h at 37 C with no test reagents. This was followed by the addition of insulin for 20 min (no insulin added for basal uptake), before the addition of 0·1 m 2-deoxy-- [2,6- 3 H]glucose (0·5 mCi/mmol) for 5 min at 37 C. Uptake was terminated by rapid removal of the assay buffer, followed by three washes in ice-cold PBS. Cells were lysed with 0·5  NaOH/0·1% sodium dodecyl sulfate (SDS); the lysates were added to 10 ml Ready Gel (Beckman, Palo Alto, CA, USA) and counted in a Beckman LS 6000 IC counter.
Measurement of cAMP
Cells grown in 12-well plates were treated with insulin and GLP-1 as described above and then washed three times with ice-cold PBS before cAMP extraction with 1 ml ice-cold 0·6 m perchloric acid. The extracts (950 µl) were transferred to microcentrifuge tubes and the pH adjusted to 7·0 using 5  K 2 CO 3 . After centrifugation for 5 min at 2000 g, the supernatant was vacuum dried, and then recovered in 500 µl 500 m Tris (pH 7·5) and 4 m EDTA. Fifteen minutes after the addition of 0·15 m Na 2 CO 3 (50 µl) and 0·15 m ZnSO 4 (50 µl) and incubation on ice, the salt precipitate was removed by centrifugation for 5 min at 2000 g. Aliquots of the supernatant (50 µl) were assayed using a cAMP 3 H assay kit (Amersham Corporation). After solubilization of the cells in formic acid, the protein content was measured by the Bradford method (BioRad, Richmond, CA, USA) with gamma globulin as standard.
Insulin binding
Following insulin and GLP-1 treatment, cells grown in 12-well plates were washed twice with 0·5 ml binding buffer containing 10 m Tris, pH 7·6, 120 m NaCl, 1·2 m MgSO 4 , 15 m NaOAc, and 5 m KCl. The cells were then incubated with 0·5 ml binding buffer containing 1% BSA, a range of concentrations of insulin and 3 10 5 c.p.m. of 125 I-labeled insulin (Amersham Corporation) overnight at 4 C. At the end of the incubation the supernatant was discarded and the cells were washed three times with 0·5 ml ice-cold PBS before solubilization with 0·5  NaOH/0·1% SDS. The radioactivity was measured with an ICN Apec Series gamma counter. Specific binding was determined by subtracting from total binding the radioactivity associated with cells incubated in the presence of a large excess of unlabeled insulin.
Preparation of total cellular membranes and Western blot analysis
After 24-h pretreatment with insulin and/or GLP-1, cells were washed twice with PBS without Ca 2+ and Mg 2+ and once with ice-cold washing buffer (10 m Hepes, pH 7·4, 0·25  sucrose, and 5 m EDTA). Cells were then scraped into icecold homogenization buffer (10 m Hepes, pH 7·4, 0·25  sucrose, 5 m EDTA, 0·2 m phenylmethylsulfonyl fluoride (PMSF), 20 µg/ml aprotinin, and 10 µg/ml leupeptin) and homogenized twice with a polytron (Brinkman Instruments, Westbury, NY, USA) at a setting of 7·5 for 15 s. The homogenate was centrifuged at 2000 g for 5 min at 4 C. The clarified supernatant was centrifuged at 110 000 g (70Ti; Beckman) for 1 h at 4 C. The pellet containing total cellular membranes was resuspended in the membrane buffer (50 m Hepes, pH 7·4, 0·25  sucrose, 20 µg/ml aprotinin, 10 µg/ml leupeptin, and 0·2 m PMSF), aliquoted and stored at 70 C. Crude membranes (50 µg each sample) were solubilized in Laemmli sample buffer (Laemmli 1970) and then subjected to SDS-polyacrylamide gel electrophoresis on a gradient 4-12% gel (Novex, San Diego, CA, USA) and transferred electrophoretically to PVDF membrane. The membrane was incubated for 1 h at room temperature in blocking buffer (20 m Tris-HCl, pH 7·6, 137 m NaCl, 0·1% Tween 20, and 5% BioRad Blocker), washed once with washing buffer (20 m Tris-HCl, pH 7·6, 137 m NaCl, and 0·1% Tween 20) and treated with polyclonal anti-GLUT1 or anti-GLUT4 antibodies (Charles River Pharmservices, Southbridge, MA, USA) for 1 h at room temperature. After a series of washes, the membranes were incubated in the blocking buffer containing donkey anti-rabbit antibodies conjugated with horseradish peroxidase (Oncogene Science, Uniondale, NY, USA) for 1 h. PVDF membranes after several washes were immersed in ECL detection reagent (Amersham Corporation) for 1 min at room temperature and exposed to hyperfilm-ECL (Amersham Corporation). The images were quantified by laser densitometry (ImageQuant, Molecular Dynamics, Sunnyvale, CA, USA).
RNA isolation and Northern blot analysis
Cells were homogenized in guanidium isothiocyanate, followed by ultracentrifugation on a 5·7  cesium chloride cushion (Glisin et al. 1974) . For Northern blot analysis, 15 µg total RNA was separated by electrophoresis in 1% agarose, 2  formaldehyde gels, transferred to nylon membrane (Schleicher and Schuell, Keene, NH, USA) and fixed by cross-linking with a u.v. Stratalinker (Stratagene, La Jolla, CA, USA). Filters were prehybridized at 42 C for 2-3 h in 50% (v/v) formamide containing 6 SSPE (0·15  NaCl, 0·01  sodium phosphate monobasic, and 1 m EDTA), 0·1% SDS, and 1 Denhardt's solution. Hybridizations were carried out at 42 C overnight in prehybridization buffer containing GLUT4, GLUT1, insulin receptor, or -actin cDNA probe. All cDNA probes were labeled with [ 32 P]dCTP by the random priming procedure using Sequenase (US Biochemical, Cleveland, OH, USA). After hybridization, the filters were washed twice with 6 SSPE and 0·1% SDS for 30 min at room temperature, followed by another two washes of 30 min in 0·1 SSPE and 0·1% SDS at 37 C and then subjected to autoradiography using Kodak X-Omat AR film with intensifying screens. The images of developed films were quantified by laser densitometer. The 18S ribosomal RNA was then used for normalization of GLUT1 and GLUT4 mRNA levels. A method described earlier was used for oligonucleotide labeling and hybridization (Wang et al. 1995a 
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Statistical analysis
Values presented in the figures are expressed as the mean ... of at least three independent experiments. Differences between groups were analysed by the Student's t-test and repeated measures of variance using PROC GLN (SAS version 6·09) (Snedecor & Cochran 1979) .
RESULTS
2-Deoxyglucose uptake
In control 3T3-L1 adipocytes, the acute addition of insulin resulted in an eightfold increase in deoxyglucose uptake (Table 1) . However, treatment with insulin (100 n) for 24 h led to a significant decline in acute insulin-mediated glucose uptake. This was accounted for by an elevation in basal uptake. In cells pretreated with GLP-1 (10 n) for 24 h, basal glucose uptake was increased twofold, with a slight but significant increase in acute insulin-stimulated glucose uptake when compared with control cells (P<0·05). Pretreatment with both insulin and GLP-1 led to results similar to those found in pretreatment with insulin alone, e.g. increased basal uptake. There was, however, a slight increase in the acute insulin-mediated glucose uptake above the levels seen with prolonged exposure to both insulin and GLP-1 alone.
Effects of insulin and GLP-1 on GLUT1 and GLUT4 total protein levels
We investigated further the effects of 24-h exposure of differentiated 3T3-L1 adipocytes to either insulin or GLP-1, or both together, by measuring the total cellular content of GLUT1 and GLUT4 proteins. A Western blot analysis from a representative experiment is shown in Fig. 1A . Consistent with published data, treatment with insulin significantly increased the levels of GLUT1, reaching a maximum effect at 10 n insulin (Fig. 1B,  P<0·001 ). Insulin (10 and 100 n) increased GLUT1 protein content by about 100% (Fig. 1B) , but decreased GLUT4 protein in a concentrationdependent manner. Insulin (10 n) decreased  1. Effects of insulin and GLP-1 on GLUT1 and GLUT4 protein content in total membrane extracts from 3T3-L1 adipocytes. 3T3-L1 adipocytes cultured for 24 h in the presence or absence of various concentrations of insulin and/or GLP-1 were harvested and total membrane extracts collected. Total membrane preparations (50 µg) were analyzed by Western blotting for the presence of GLUT1 and GLUT4. The data are expressed as a percentage of the value observed in the untreated cell cultures. (A) The blots represent one individual experiment, while (B and C) the bar graphs indicate the mean ... of three independent Western blot analyses. Statistical significance between cells treated with either insulin alone vs untreated cells (*) or GLP-1 (G) vs untreated cells or insulin-treated cells was evaluated as described in Materials and Methods: *=P<0·05, **=P<0·001, G=P<0·001.
GLUT4 by about 30% (P<0·05) while 100 n decreased it by 70% (P<0·01) (Fig. 1C, n=3) . GLP-1 alone increased both the levels of GLUT1 and GLUT4 proteins approximately twofold (P<0·001, n=3). However, its effect on GLUT1 was not additive to that of insulin. Its effect on GLUT4 is therefore completely opposite from that seen with insulin. GLP-1 also completely prevented the decline in GLUT4 protein induced by 100 n insulin.
Effects of insulin and GLP-1 on the expression of GLUT1 mRNA
Northern blot analysis indicated a threefold increase in the expression of GLUT1 mRNA by insulin ( Fig. 2, n=3; P<0·0001) . The same response was obtained with 10 or 100 n insulin. These results are in agreement with those from GLUT1 protein determination (Fig. 1) . In contrast to its effects on GLUT1 protein, GLP-1 had no effect on GLUT1 mRNA, nor did it influence the effect of insulin on GLUT1 expression when given concurrently.
Effects of insulin and GLP-1 on the expression of GLUT4 mRNA
There was a dose-dependent reduction in GLUT4 mRNA expression following a 24-h pretreatment with insulin (Fig. 3) . While 10 n insulin caused a 45% reduction in GLUT4 mRNA levels (P<0·01), only 12·5% of GLUT4 mRNA remained after the addition of 100 n insulin (P<0·001). GLP-1 (10 n) alone did not influence expression of the GLUT4 gene, but it almost completely prevented the reduction in mRNA levels induced by 10 n insulin. Moreover, GLP-1 lessened the influence of 100 n insulin on GLUT4 gene expression, such that the levels of GLUT4 mRNA were 25% that in control cells. We tested the effect of exendin-4, a potent agonist of GLP-1 (Goke et al. 1993) , to see if it mimicked the action of GLP-1 on preventing down-regulation of GLUT4 by insulin. Exendin-4 (10 n) was actually more potent than GLP-1 (10 n) at preventing down-regulation of GLUT4 mRNA by insulin (data not shown). Exendin-(9-39) (100 n), an antagonist at the GLP-1 receptor in the pancreas and brain (Goke et al. 1993 , Wang et al. 1993b , did not antagonize the effects of GLP-1 on GLUT4 mRNA in the presence of insulin (data not shown). In fact it behaved like GLP-1. This peptide has been shown to be an agonist in 3T3-L1 adipocytes (MontroseRafizadeh et al. 1997) .
Intacellular cAMP, insulin binding, and mRNA levels of the insulin receptor
No difference was observed between control cells and cells treated with insulin, GLP-1, or both together with regards to cAMP production, insulin binding or insulin receptor mRNA levels (data not shown).
 2. Effects of insulin and GLP-1 on GLUT1 mRNA levels in 3T3-L1 adipocytes. 3T3-L1 adipocytes cultured for 24 h in the presence or absence of various concentrations of insulin and/or GLP-1 were harvested and cellular RNA extracted. Total RNA (15 µg) was analyzed by Northern hybridization for the presence of GLUT1 and -actin mRNAs. The data were normalized by hybridizing the same membrane with the 18S oligonucleotide probe ( -actin expression was increased by insulin treatment) and are expressed as a percentage of the value observed in the untreated cells. (A) The blots represent one individual experiment, while (B) the bar graph indicates the mean ... of three independent Northern blot analyses. Statistical significance between treated and untreated cells was evaluated as described in Materials and Methods. *=P<0·0001.
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DISCUSSION
Prolonged exposure of cultured adipocytes to insulin results in decreased levels of GLUT4 mRNA (Flores-Riveros et al. 1993 ) and down-regulation of GLUT4 glucose transporters at the plasma membrane (Kozka et al. 1991) . However, primary cultures of rat adipocytes also have reduced levels of GLUT4 even when no insulin is added to the medium (Hadjuch et al. 1992 , Sivitz et al. 1992 , Gerrits et al. 1993 , suggesting that insulin is not the only factor modulating facilitative glucose transporters. It also suggests that factors modulating glucose transport in vivo are not present in vitro and that in vivo factors are necessary for the full expression of glucose transporters. Our results indicate that incretins may be one such factor.
We have already shown that GLP-1 has acute effects on glucose metabolism in 3T3-L1 adipocytes (Egan et al. 1994) . In vivo studies in humans have also shown that GLP-1 has effects on glucose disposal (Gutniak et al. 1992 , D'Alessio et al. 1994 . The presence of GLP-1 for 24 h nearly doubled the content of both GLUT4 and GLUT1 protein levels in 3T3-L1 adipocytes compared with control cells. Furthermore, basal and insulin-stimulated deoxyglucose uptake was increased, giving physiological significance to these protein changes. However, mRNA levels for both transporters was not altered. These results suggest that GLP-1 modulates insulin action via increasing the rate of translation or the protein stability of the transporters.
Our data indicate that GLP-I has the ability to lessen insulin-induced down-regulation of both GLUT4 mRNA and protein but is not able to reverse the negative effects of the continued presence of insulin on glucose transport. In adipose tissue and skeletal muscle, insulin-stimulated glucose uptake is a result of translocation of GLUT4 transporters from the intracellular compartment to the plasma membrane (Simpson & Cushman 1986 , Gould & Bell 1990 . It has been shown previously that prolonged exposure to insulin causes 3T3-L1 adipocytes to lose their ability to acutely increase glucose uptake in response to insulin (FloresRiveros et al. 1993 ). This appears to be due to a decrease in transporter translocation to the plasma membrane because long-term exposure to insulin induces an insulin-resistant state whereby phosphatidylinositol 3-kinase is rendered ineffectual and translocation is prevented (Ricort et al. 1995) . It is possible that while GLP-1 can prevent the down-regulation of GLUT4 protein, it cannot prevent the inhibition of GLUT4 translocation caused by insulin. Interaction between insulin and GLP-1 appears to be specific for the transporter subtype, as GLP-1 did not synergize with insulin as regards GLUT1 (both insulin and GLP-1 caused increased levels of GLUT1 mRNA and protein content), but prevented GLUT4 down-regulation by insulin. Insulin and dexamethasone have been shown to synergize in adipocytes with regards to their effects on GLUT4 gene expression (Hadjuch et al. 1995) . To our knowledge, however, this is the first time a factor has been shown to prevent the decline in GLUT4 mRNA levels induced by insulin in 3T3-L1 adipocytes.
cAMP has been shown to decrease GLUT4 expression in 3T3-L1 adipocytes (Kaestner et al. 1991). In this study, it appears that GLP-1 and/or insulin caused no change in cAMP levels in the cells when monitored throughout the 24 h of treatment. However, there may be small, biologically significant changes in cAMP, perhaps even at a critical time, induced by these agents in subcompartments of the cells not detected by our relatively crude assay. One might postulate that the cAMP levels, which should be lowered by insulin in a counterregulatory fashion, are abnormally high and that in fact this lack of suppression of cAMP by insulin is exacerbating the down-regulation of GLUT4. It has already been shown that 8-bromo-cAMP and insulin have additive effects on repressing transcription of GLUT4 mRNA (Flores-Riveros et al. 1993) . GLP-1 did not appear to modulate the cAMP levels, or insulin's lack of effect on cAMP. These findings are in contrast to the situation in the pancreas where GLP-1 is known to increase cAMP levels in cells (Drucker et al. 1987) . Our recent study (Montrose-Rafizadeh et al. 1997) suggested that the action of GLP-1 in 3T3-L1 adipocytes may be mediated via a functionally different receptor from the GLP-1 receptor.
Insulin binding was not altered by prolonged exposure to insulin or GLP-1. We had already shown that short incubations with GLP-1 did not alter insulin binding (Egan et al. 1994) . No effect on insulin receptor gene expression was observed following a 24-h incubation with insulin alone or with GLP-1. Therefore, GLP-1 does not appear to directly affect expression or intrinsic activity of the insulin receptor per se. GLUT1 mRNA and protein levels were increased by both insulin and GLP-1 when given for 24 h, in keeping with increased basal levels of hexose uptake. It has been noted in vivo in non-insulin-dependent diabetes mellitus (NIDDM), a classic insulin-resistant state, that basal glucose uptake is increased while the insulinmediated response is decreased. Fasting GLP-1 levels are in fact increased in NIDDM (Gutniak et al. 1992) , and this could possibly explain the increased basal uptake seen in this condition. To our knowledge this is the first demonstration of a modulation of transporters in an insulin-sensitive tissue by any of the hormones produced in the gut. As the levels of several gut hormones increase after eating, this raises the possibility that the transporters in insulin-sensitive tissues may be regulated by many other factors that may work alone or in concert.
